Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15811680 | 0.85 | — | — | |
| SCHEMBL2754578 | 0.85 | TSHR (0.31) | CYP2C9TSHR | |
| SCHEMBL2754589 | 0.85 | TSHR (0.31) | CYP2C9TSHR | |
| SCHEMBL14296166 | 0.85 | TSHR (0.31) | CYP2C9TSHR | |
| SCHEMBL16645134 | 0.84 | CYP2C9 (0.30) | CYP2C9TSHR | |
| SCHEMBL17573226 | 0.82 | PRKCA (0.31) | — | |
| SCHEMBL18602065 | 0.80 | — | — | |
| SCHEMBL10067038 | 0.80 | CYP2C9 (0.34) | CYP2C9TSHR | |
| SCHEMBL20861946 | 0.80 | ALDH1A1 (0.36) | — | |
| SCHEMBL12192290 | 0.80 | PRKCA (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9849191-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-9770519-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-20170266311-A1 | NaPi2b-targeted Antibody-Drug Conjugates and Methods of Use Thereof | MERSANA THERAPEUTICS, INC. | 2017-09-21 | — | — | US | disclosed |
| US-20160220696-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2016-08-04 | — | — | US | disclosed |
| US-20160067353-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2016-03-10 | — | — | US | disclosed |
| US-9144615-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| WO-2015054659-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. (US) | 2015-04-16 | — | — | WO | disclosed |
| US-20150104407-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2015-04-16 | — | — | US | disclosed |
| US-20150064130-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2015-03-05 | — | — | US | disclosed |
| US-20150044160-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2015-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150104407-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, STAMBP, TSPO | CYP2C9 3394/4885TSHR 4329/4885 |
| US-20150044160-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, CLTB, BRAP | CYP2C9 4292/4885TSHR 3548/4885 |
| US-20160067353-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, CLTB, BRAP | CYP2C9 4292/4885TSHR 3548/4885 |
| US-20170266311-A1 | NaPi2b-targeted Antibody-Drug Conjugates and Methods of Use Thereof | SLC34A2, SLC34A3, SLC34A1 | CYP2C9 1629/4885TSHR 3412/4885 |
| US-20160220696-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, PEBP1, STAMBP | CYP2C9 4593/4885TSHR 3669/4885 |
| US-20150064130-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, PEBP1, STAMBP | CYP2C9 4593/4885TSHR 3669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.